Merck wins FDA OK for Noxafil tablets
This article was originally published in Scrip
Merck won approval from the US FDA its oral antifungal agent Noxafil (posaconazole) 100mg delayed-release tablets as a prophylaxis therapy for invasive Aspergillus and Candida infections in severely immunocompromised patients 13 years or older at high risk of developing those infections, like those who have undergone hematopoietic stem cell transplants (HSCT) and have graft-versus-host disease (GVHD), or patients with cancers of the blood who are experiencing prolonged neutropenia as a result of chemotherapy.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.